First Eagle Investment Management
MYGN icon

First Eagle Investment Management’s Myriad Genetics MYGN Stock Holding History

First Eagle Investment Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-368,980
Closed -$11.3M – 360
2016
Q2 		$11.3M Buy
+368,980
New +$12.8M 0.03% 175
2014
Q2 		– Sell
-284,826
Closed -$9.74M – 368
2014
Q1 		$9.74M Buy
+284,826
New +$8.82M 0.03% 144

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

First Eagle Investment Management's MYGN Position: Q3 2016 in Review

First Eagle Investment Management sold out of Myriad Genetics (MYGN) in Q3 2016, closing a stake of 368,980 shares — an estimated $11.3M sold.

First Eagle Investment Management first reported a position in MYGN in Q1 2014 and held it in 2 quarters. The position peaked at $11.3M in Q2 2016. 224 funds tracked by Wall St. Rank hold MYGN as of Q3 2016.

  • First Eagle Investment Management reported no remaining Myriad Genetics position as of Q3 2016 after selling out during the quarter.
  • First Eagle Investment Management sold 368,980 Myriad Genetics shares in Q3 2016, an estimated $11.3M.
  • First Eagle Investment Management first reported a position in Myriad Genetics in Q1 2014 and held it in 2 quarters.
  • First Eagle Investment Management's Myriad Genetics position peaked at $11.3M in Q2 2016.
  • 224 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2016.

Based on First Eagle Investment Management's 13F filing for Q3 2016, filed 7 Nov 2016.